24 Aug

AbbVie looks set to recreate Humira patent thicketing success following Imbruvica victory

US federal district court in Delaware finds four patents for blockbuster drug, Imbruvica valid and infringed in a boost that suggests AbbVie will not face competition until 2032.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth